Clinical Trials · NCT03083210
Study of Lanreotide in Metastatic or Recurrent Grade I-II Hindgut NET
- Phase
- Phase 4
- Recruitment status
- Unknown
- Sponsor
- Samsung Medical Center
- Enrollment
- 28
- Start date
- Jul 2017
- Locations
- 1 site, South Korea
- Primary endpoint
- Progression free survival